Genmab Is Too Attractive To Ignore
Portfolio Pulse from
Genmab's shares are currently at attractive levels, with strong long-term growth prospects. The company's royalty revenues are expected to exceed $2.5 billion this year, driven by Darzalex and Kesimpta, and could reach $4 billion at peak. Despite setbacks, growth is supported by Epkinly revenues, an expanding clinical pipeline, and the acquisition of ProfoundBio.
December 08, 2024 | 1:30 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Genmab's shares are at attractive levels with expected royalty revenues exceeding $2.5 billion this year, driven by Darzalex and Kesimpta. Long-term growth is supported by Epkinly revenues, an expanding clinical pipeline, and the acquisition of ProfoundBio.
Genmab's shares are considered attractive due to expected high royalty revenues and strong growth prospects. The company's focus on key products like Darzalex and Kesimpta, along with strategic acquisitions like ProfoundBio, supports a positive outlook.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100